BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 17186842)

  • 1. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
    J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism.
    Nagode LA; Chew DJ; Podell M
    Vet Clin North Am Small Anim Pract; 1996 Nov; 26(6):1293-330. PubMed ID: 8911021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O
    Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
    Sanchez CP; He YZ
    J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
    Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
    Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy.
    Schindler S; Mannstadt M; Urena P; Segre GV; Stein G
    Clin Nephrol; 2004 Apr; 61(4):253-60. PubMed ID: 15125031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum calcium concentration and the safety of vitamin D therapy].
    Ikeda Y; Takemoto F
    Clin Calcium; 2004 Sep; 14(9):79-82. PubMed ID: 15577116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
    Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
    Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches.
    Ouseph R; Leiser JD; Moe SM
    J Am Soc Nephrol; 1996 Mar; 7(3):497-505. PubMed ID: 8704117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
    Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
    Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
    Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
    Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia.
    Jara A; Chacón C; Valdivieso A; Aris L; Jalil R; Felsenfeld AJ
    Nephrol Dial Transplant; 2001 May; 16(5):1009-16. PubMed ID: 11328908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.